Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Shares of Cambridge, Mass.-based Sarepta have fallen by more than 90% in the last year amid safety concerns about its Elevidys, a gene therapy that treats Duchenne muscular dystrophy, following ...

Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

On the other hand, H.C. Wainwright raised Arrowhead's stock price target from $60.00 to $80.00, citing the company's recent global license and collaboration agreement with Sarepta Therapeutics.

Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...

Sarepta’s new clinical programs from Arrowhead aim to treat facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, idiopathic pulmonary fibrosis and spinocerebellar ataxia 2.

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases.